GILD - Long-term volatility squeeze breakout?Possibly breaking out of first squeeze since 2010, which resulted in a helluva run.by PivotPointsPublished 3
GILD Falling WedgesGILD seems to be forming a long term bottom, the presence of two falling wedges displays the possible repeating bullish nature of this chart. Green fractal indicates a long term target price of ~100. If downsides occur a stop loss is placed. MACD can be observed to be also rising. Volume is not always a great indicator of price movement but in a more mature market such as this, volume spikes can be interpreted as bullish signs.by BixleyUpdated 3
Added GILD hereentered long on possible longterm breakout reversalLongby fallingumbrellamanPublished 4
GILD - DAILY CHARTHi, today we are going to talk about GILD and its current landscape. We can observe at this timeframe, a confluence of technical factors, that entail a setup which might drive this asset to a new movement. The details of our analysis are highlighted in the chart above. Want to know more about our trades and ideas? Join the Traders Heaven today. Thank you for reading and leave your comments if you like. To have access to our exclusive contents, and see more of our work, join the Traders Heaven today! Link Below. Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial adviceby Igor-SilvaPublished 36
$GILD double inside daysupdate from last week, over weekly downtrend and now double inside days, setting up for a move by Option_TradersPublished 3
GILD cleared downtrendHard to believe but GILD finally closed a daily candle over the downtrend. Lets see if the move can continue, follow the chartby Option_TradersPublished 5
GILD broke wedge to the upside. $80 likely next stopGILD broke wedge to the upside. $80 likely next stopLongby RyanDreBachPublished 1
Time to get defensive in $GILDThe global slowdown is coming and it is time to get defensive. Here we are reaching the end of the road to the downside in Gilead and a perfect instrument to work the flows with. We are tracking a break of the channel to unlock the +11% move. Let's see how it plays out over the coming days. Best of luckLongby ridethepigUpdated 9
GILD ready to break outBounce off resistance. Had strong volume to get there. Above all the EMA's. Waiting for this to pullback a little farther to jump in. Stop below the previous weeks' candle. Longby BruceD975Published 3
GILD - Nov 15I totally missed this rally after the breakout from 64. Previous resistance is at 69. It would be interesting to see how GILD performs around that level. Watching for a jump of the cliff move from the ladder it is climbing. Targeting long 65 Put Nov 15.by imzeeshanPublished 5
GILD TECHNICAL ANALYSIS CHART PATTERNFRIENDS AFTER LONG DOWN TREND NOW WE HAVE SEEN A TRIPLE BOTTOM PATTERN IN MY OPINION AFTER BREAKING THE NECKLINE IT WILL GO FOR LONG TIL THE NEXT RESISTANCE AREA OR MORE. NOTE: WE CANT ENTER THE TRADE UNTIL IT BREAK THE NECKLINE OF THE PATTERN.Longby AdeelMahmoodPublished 334
$GILD BREAKOUT ON THE WAY IN GILEAD SCIENCES INCGilead traded well today on the news it will be investing $5.1 billion in EURONEXT:GLPG which will raise its stake from 12% to 22% with the a future target of 29.9% ownership on approval by the shareholders of Galapagos. The market seems happy with the move, even as biotech stocks have been under pressure lately. Decisions out of the White House haven't been helping, as the government continues to keep a close eye on drug prices. Also on Monday Wells Fargo analysts upgraded Gilead Sciences to an outperform rating and slapped an $88 price target on the name. That implies 33% upside from Friday's closing price and would send Gilead stock more than 10% above its 52-week high. AVERAGE ANALYSTS PRICE TARGET $88 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT P/E RATIO 15 SHORT INTEREST 1% Company Description Gilead Sciences , Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. Longby RedHotStocksPublished 2214
GILD nearing pullback at top of long-term channelGILD nearing pullback at the top of it's multiyear channel.Shortby RyanDreBachPublished 3
GILD Showing some positive price actionTesting the top of a long term range. May fall back but if it breaks and pushes through 200 could see a significant move up.Longby WadeYendallPublished 7